Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on conduction system disease

JAMA Internal Medicine

Volumn 176, Issue 8, 2016, Pages 1085-1092

  Dewland, Thomas A ^a   Soliman, Elsayed Z ^b   Davis, Barry R ^c   Magnani, Jared W ^c   Yamal, Jose Miguel ^d   Piller, Linda B ^d   Haywood, L Julian ^e   Alonso, Alvaro ^f   Albert, Christine M ^g   Marcus, Gregory M ^h  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE BESYLATE; CHLORTALIDONE; DOXAZOSIN MESYLATE; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ADULT; AMBULATORY CARE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; FOLLOW UP; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE CONDUCTION SYSTEM; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE CONDUCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SECONDARY ANALYSIS; AGED; CARDIOVASCULAR DISEASES; DIAGNOSTIC IMAGING; DRUG EFFECTS; ELECTROCARDIOGRAPHY; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CHLORTHALIDONE; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; LISINOPRIL; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84980318181     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.2502     Document Type: Article

References (42)

1. Zhang Z-M, Rautaharju PM, Soliman EZ, et al. Mortality risk associated with bundle branch blocks and related repolarization abnormalities (from the Women's Health Initiative [WHI]). Am J Cardiol. 2012;110(10):1489-1495.
2. Badheka AO, Singh V, Patel NJ, et al. QRS duration on electrocardiography and cardiovascular mortality (from the National Health and Nutrition Examination Survey-III). Am J Cardiol. 2013;112(5): 671-677.
3. Stephenson K, Skali H, McMurray JJV, et al. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. Heart Rhythm. 2007;4(3): 308-313.
4. Mandyam MC, Soliman EZ, Heckbert SR, Vittinghoff E, Marcus GM. Long-term outcomes of left anterior fascicular block in the absence of overt cardiovascular disease. JAMA. 2013;309(15): 1587-1588.
5. Cheng S, Keyes MJ, Larson MG, et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA. 2009;301(24):2571-2577.
6. Magnani JW, Wang N, Nelson KP, et al; Health, Aging, and Body Composition Study. Electrocardiographic PR interval and adverse outcomes in older adults: the Health, Aging, and Body Composition Study. Circ Arrhythm Electrophysiol. 2013;6(1):84-90.
7. Schneider JF, Thomas HE Jr, Kreger BE, McNamara PM, Kannel WB. Newly acquired left bundle-branch block: the Framingham Study. Ann Intern Med. 1979;90(3):303-310.
8. Schneider JF, Thomas HE, Kreger BE, McNamara PM, Sorlie P, Kannel WB. Newly acquired right bundle-branch block: the Framingham Study. Ann Intern Med. 1980;92(1):37-44.
9. Thrainsdottir IS, Hardarson T, Thorgeirsson G, Sigvaldason H, Sigfusson N. The epidemiology of right bundle branch block and its association with cardiovascular morbidity: the Reykjavik Study. Eur Heart J. 1993;14(12):1590-1596.
10. Eriksson P, Hansson PO, Eriksson H, Dellborg M. Bundle-branch block in a general male population: the study of men born 1913. Circulation. 1998;98(22):2494-2500.
11. Bussink BE, Holst AG, Jespersen L, Deckers JW, Jensen GB, Prescott E. Right bundle branch block: prevalence, risk factors, and outcome in the general population: results from the Copenhagen City Heart Study. Eur Heart J. 2013;34(2):138-146.
12. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23): 2981-2997.
13. Davis BR, Cutler JA, Gordon DJ, et al; ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). AmJ Hypertens. 1996;9(4 Pt 1):342-360.
14. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998-3007.
15. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283(15):1967-1975.
16. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation. 1987;75(3): 565-572.
17. Prineas RJ, Crow RS, Blackburn HW. The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurements and Classifications. Littleton, MA: John Wright-PSG Inc; 1982.
18. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;104(21): 2608-2614.
19. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation. 2004;110(16):2313-2319.
20. Haywood LJ, Ford CE, Crow RS, et al; ALLHAT Collaborative Research Group. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J AmColl Cardiol. 2009;54(22):2023-2031.
21. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ; Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation. 1997;95(8): 2007-2014.
22. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1995;91(3):698-706.
23. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: ameta-analysis of randomized double-blind studies. JAMA. 1996;275(19): 1507-1513.
24. Mathew J, Sleight P, Lonn E, et al; Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin converting enzyme inhibitor ramipril. Circulation. 2001;104(14):1615-1621.
25. Moss AJ, Hall WJ, Cannom DS, et al; MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329-1338.
26. Cleland JGF, Daubert J-C, Erdmann E, et al; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15): 1539-1549.
27. Davis BR, Piller LB, Cutler JA, et al; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation. 2006;113(18):2201-2210.
28. Fahy GJ, Pinski SL, Miller DP, et al. Natural history of isolated bundle branch block. Am J Cardiol. 1996;77(14):1185-1190.
29. Freedman RA, Alderman EL, Sheffield LT, Saporito M, Fisher LD. Bundle branch block in patients with chronic coronary artery disease: angiographic correlates and prognostic significance. J AmColl Cardiol. 1987;10(1):73-80.
30. Sumner G, Salehian O, Yi Q, et al; HOPE Investigators. The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial. J Cardiovasc Electrophysiol. 2009;20(7):781-787.
31. Hesse B, Diaz LA, Snader CE, Blackstone EH, Lauer MS. Complete bundle branch block as an independent predictor of all-cause mortality: report of 7,073 patients referred for nuclear exercise testing. Am J Med. 2001;110(4):253-259.
32. Aro AL, Anttonen O, Tikkanen JT, et al. Intraventricular conduction delay in a standard 12-lead electrocardiogram as a predictor of mortality in the general population. Circ Arrhythm Electrophysiol. 2011;4(5):704-710.
33. Barsheshet A, Goldenberg I, Garty M, et al. Relation of bundle branch block to long-term (four-year) mortality in hospitalized patients with systolic heart failure. Am J Cardiol. 2011;107(4): 540-544.
34. Davies M, Harris A. Pathological basis of primary heart block. Br Heart J. 1969;31(2):219-226.
35. Demoulin JC, Simar LJ, Kulbertus HE. Quantitative study of left bundle branch fibrosis in left anterior hemiblock: a stereologic approach. Am J Cardiol. 1975;36(6):751-756.
36. Halaweish I, Alam HB. Changing demographics of the American population. Surg Clin North Am. 2015;95(1):1-10.
37. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8(1):29.
38. Jensen PN, Gronroos NN, Chen LY, et al. Incidence of and risk factors for sick sinus syndrome in the general population. J Am Coll Cardiol. 2014; 64(6):531-538.
39. Alonso A, Agarwal SK, Soliman EZ, et al. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009;158 (1):111-117.
40. Marcus GM, Alonso A, Peralta CA, et al; Candidate-Gene Association Resource (CARe) Study. European ancestry as a risk factor for atrial fibrillation in African Americans. Circulation. 2010; 122(20):2009-2015.
41. Dewland TA, Olgin JE, Vittinghoff E, Marcus GM. Incident atrial fibrillation among Asians, Hispanics, blacks, and whites. Circulation. 2013;128 (23):2470-2477.
42. Menon DV, Arbique D, Wang Z, Adams-Huet B, Auchus RJ, Vongpatanasin W. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab. 2009;94(4):1361-1366.